Nebenwirkungen · Nulojix
NULOJIX 250 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-213624 · Präparat HOS-155150
Long-term extension in Study 1 and Study 2 Of the 1209 randomised and newly transplanted patients in the two Phase 3 studies (see section 5.1), 761 patients continued after Year 3 in a long-term extension period for up to an additional 4 years and continued to receive the study drug according to their original treatment assignment. As compared to the results from the initial 3 years, no new adverse reactions or increasing incidence of adverse reactions (listed above from the initial 3-year period) were detected during the 4-year long-term open label extension.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-20T13:32:00Z · SHA-256 699ad0365be092c03037bcab8ddbe9297f4376d0afffb7e9c952313b11ba0943 · Passage 35cb391aa7cae7ba7c2b54b4b77058e62d944f87bbaa2b9238de194b12a70c5d · Zeichen 9881–10447 im Abschnitt